# Acutus Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acutus-medical

- Industry: Medical Devices & Equipment
- Headquarters: Carlsbad, US
- Website: www.acutusmedical.com
- Total disclosed funding: $210M
- Latest round: Series D (Jun 12, 2019)
- Investors on record: 11

## About

Founded in 2011 and based in California, US, Acutus Medical, Inc. operates as a developer of healthcare equipment for cardiac electrical activation visualization. The company was founded by Randy Werneth. In June 2019, Acutus Medical, Inc. raised USD 70 million in Series D funding from returning investors Deerfield Management and OrbiMed Advisors. The company released its IPO in May 2020 under the ticker symbol AFIB and raised USD 159 million. The company has 224 employees as of June 2020.

The company is focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus offers a broad portfolio of differentiated electrophysiology products that enable physicians to treat patients and provides its customers with solutions for the catheter-based treatment of cardiac arrhythmias. The company's AcQMap technology provides high-resolution imaging and mapping system which provides clear and consistent high-resolution maps for improved diagnosis. The company's platform is also an intracardiac mapping system that uses 3D imaging and displays the heart’s true activation pattern. Real-time dipole density mapping and the electrical activation of the heart chambers can be seen which doctors can use to identify the locations that cause the arrhythmia. The AcQMap Patient Electrode Kit helps in catheter localization. The SuperMap technology enables mapping of stable, repetitive rhythms in less than 3 minutes and the Contact Mapping technology enables Multipoint electroanatomic mapping for simple arrhythmias. AcQCross Qx dilator provides safe transseptal access.

Acutus Medical revenue was USD 8.46 million as of December 2020.

## Funding rounds

- Series D, Jun 12, 2019, $107M — OrbiMed Advisors, GE Capital Equity, Deerfield Management, Pura Vida Investments, Xeraya Capital, 8VC, Advent Life Sciences, Opaleye Management
- Series C, Mar 14, 2016, $75M — GE Capital, Equity, OrbiMed Advisors, Deerfield Management, Xeraya Capital, Advent Life Sciences
- Series B, Aug 15, 2013, $1.8M — GE Capital, Equity, Index Ventures, OrbiMed Advisors, Advent Venture Partners
- Series B, Jun 7, 2013, $21M — Index Ventures, OrbiMed Advisors, Advent Life Sciences
- Seed, Sep 30, 2011, $3.3M — Index Ventures
- Series A, Sep 30, 2011, $2.2M — Advent Life Sciences

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Seed, Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A, Series B, Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D
- GE Capital, Equity (https://capitalatlas.ai/funds/ge-capital-equity) — Series B, Series C
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C, Series D
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series C, Series D
- GE Capital Equity — Series D
- Pura Vida Investments (https://capitalatlas.ai/funds/pura-vida-investments) — Series D
- 8VC (https://capitalatlas.ai/funds/8vc) — Series D
- Opaleye Management — Series D